This study is about testing different treatments for glioblastoma (GBM), a type of brain cancer. It is called the GBM AGILE trial and is an international research project. The goal is to figure out which treatments work best for different groups of patients with either new or recurring GBM. Patients will participate in this study based on specific criteria and their response to the treatments will help decide the best option for them using a statistical method called Bayesian response adaptive randomization. The main focus is to improve how long patients live. This trial allows researchers to test many drugs from different companies at the same time, and they can add new treatments as they are discovered.

• The study requires regular visits for check-ups and evaluations.
• Participants will not receive other GBM treatments outside this trial while participating.
• There are specific health criteria to join, including age and health status.